Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Nuclear Medicine > THERAPY > Flashcards

THERAPY Flashcards

1
Q

Radionuclide therapy is used in:
a. Oncology
b. Endocrinology
c. Rheumatology
d. All of the above

A

D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Radionuclide radiation causes:
a. Ionization
b. Inflammation
c. Tissue necrosis
d. All of the above

A

D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

DNA damage caused by ionisation is:
a. Direct
b. Indirect
c. Direct and indirect

A

C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

α particles usualy causes:
a. Reparable damage
b. Irreparable damage
c. Reparable / irreparable damage

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Theranostic is:
a. Usage of the same or similar compounds for diagnosis and therapy
b. Use of various compounds for diagnosis and therapy
c. None of the above

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Iodine 131 is used for therapy of:
a. Benign thyroid disease
b. Malignant diseases of the thyroid gland
c. Malignant and benign thyroid diseases

A

C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Indications for the use of 131 I in benign thyroid diseases are:
a. Treatment of hyperthyroidism
b. Size reduction in non-toxic multinodular goiter
c. All of the above
d. None of the above

A

C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

After 131I reduction of thyroid function is usually expected within:
a. 1-3 months
b. 3-6 months
c. 6-9 months
d. 9-12 months

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Differentiated thyroid carcinomas (DTCs) are treated with:
a. Thyroidectomy
b. Application of iodine- 131 I
c. Lifelong substitution withl-thyroxine
d. All of the above

A

D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Radioiodine therapy is performed :
a. Six or more months after ablation
b. When an increase in serum Tg is detected
c. When recurrence or relapse of thyroid carcinoma is detected
d. All of the above

A

D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Radioactive iodine enters the thyroid cells by :
a. Active transport via NIS
b. Passive difusion
c. Via SSTR receptors
d. None of the above

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Treatment success rate after 131I ablation is :
a. About 50%
b. About 80%
c. About 90%
d. None of the above

A

C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Neuroendocrine tumors (NET) can be treated :
a. Surgically
b. With biological therapy
c. With radionuclide therapy
d. All of the above

A

D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

PRRT for neuroendocrine tumors targeting:
a. SSTR 1 receptors
b. SSTR 2 receptors
c. SSTR 5 receptors
d. All of the above

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

The number of PRRT cycles is ideally :
a. 4
b. 6
c. 12
d. None of the above

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Patients planning PRRT must have :
a. Positive test on somatostain receptor scintigraphy
b. Positive test on PET scan with 68Ga-DOTA
c. 1 or 2
d. None of the above

A

C

17
Q

Patients planning PRRT must have :
a. Positive test on somatostain receptor scintigraphy
b. Positive test on PET scan with 68Ga-DOTA
c. 1 or 2
d. None of the above

A

C

18
Q

Patients planning PRRT must have :
a. Positive test on somatostain receptor scintigraphy
b. Positive test on PET scan with 68Ga-DOTA
c. 1 or 2
d. None of the above

A

C

19
Q

The results of neuroendocrine tumors PRRT are:
a. Tumor mass reduction
b. Clinical and biochemical improvement
c. Increased survival time and quality of life
d. All of the above

A

C

20
Q

131I-meta-iodobenzylguanidine (131I-mIBG) is:
a. Norepinephrine analog
b. Somatostatin analog
c. All of the above

A

A

21
Q

Preparation for 131I-mIBG therapy involves:
a. Discontinuation of certain groups of drugs
b. Application of stable iodine
c. All of the above
d. None of the obove

A

C

22
Q

The effects of (131I-mIBG) therapy are:
a. Reduced clinical symptoms
b. Reduced volume of the tumor
c. All of the above
d. None of the above

A

C

23
Q

Radiopharmaceuticals used for Palliation of pain in bone metastases are:
a. 89Sr – chloride
b. 153Sm-EDTMP
c. 186Re / 188Re-HEDP
d. All of the above

A

D

24
Q

The main goals of 223RaCl2 therapy are:
a. Prolonged survival, prolonged time to the first symptomatic bone event, improved quality of
life.
b. Improved quality of life and pain reduction
c. Reduced volume of the tumor
d. All of the above

A

A

25
Q

Radiopharmaceuticals for therapy of metastatic castration-resistant prostate carcinoma are :
a. 177Lu-PSMA small molecule inhibitors
b. 131I MIBG
c. 177LuDOTATAE
d. All of the above

A

A

26
Q

The effects of 177LuPSMA therapy are :
a. decrease in serum PSA levels
b. reduced pain from bone metastases
c. objective remission
d. improved quality of life
e. All of the above

A

E

27
Q

Radiopharmaceuticals for radioimmunotherapy of non-Hodgkin's lymphoma are :
a. 90Y-ibritumomab tiuxetan and 90Y-epratuzumab tetraxetan
b. 90Y PSMA
c. 177Lu DOTATATE
d. All of the above

A

A

28
Q

Ibritumomab tiuxetan monoclonal antibodies binds to:
a. CD20 antigens
b. SSTR receptors
c. Norepinephrine transporters
d. All of the above

A

A

29
Q

The choice of radiopharmaceutical for radiosynoviectomy depends on:
a. The size of the joint
b. Clinical signs
c. Biochemical stage of disease
d. All of the above

A

A

Nuclear Medicine (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions